TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 157 in Subjects With Mild Atopic Asthma
Brief Summary: The purpose of this study is to assess the late and early asthmatic response after an allergen inhalation challenge in adults with mild atopic asthma after receiving multiple doses of tezepelumab (AMG 157), as well as the safety, tolerability, immunogenicity, and pharmacokinetics of multiple doses of tezepelumab in adults with mild atopic asthma.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Tezepelumab 700 mg; Type: EXPERIMENTAL; Interventions: Biological: Tezepelumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: Tezepelumab; Assigned to Arm(s): Tezepelumab 700 mg
B: Arm Label: Benralizumab Arm A; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Arm Label: Benralizumab Arm B; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Intervention Type: BIOLOGICAL; Name: Benralizumab; Assigned to Arm(s): Benralizumab Arm A | Intervention Type: BIOLOGICAL; Name: Benralizumab; Assigned to Arm(s): Benralizumab Arm B
C: Arm Label: huMAb OX40L; Type: EXPERIMENTAL; Interventions: Drug: huMAb OX40L | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: huMAb OX40L; Assigned to Arm(s): huMAb OX40L | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: Benralizumab; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Intervention Type: BIOLOGICAL; Name: Benralizumab; Assigned to Arm(s): Benralizumab

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 157 in Subjects With Mild Atopic Asthma
Brief Summary: The purpose of this study is to assess the late and early asthmatic response after an allergen inhalation challenge in adults with mild atopic asthma after receiving multiple doses of tezepelumab (AMG 157), as well as the safety, tolerability, immunogenicity, and pharmacokinetics of multiple doses of tezepelumab in adults with mild atopic asthma.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Tezepelumab 700 mg; Type: EXPERIMENTAL; Interventions: Biological: Tezepelumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: Tezepelumab; Assigned to Arm(s): Tezepelumab 700 mg
B: Arm Label: Mepolizumab Arm; Type: EXPERIMENTAL; Interventions: Biological: Mepolizumab | Intervention Type: BIOLOGICAL; Name: Mepolizumab; Assigned to Arm(s): Mepolizumab Arm
C: Intervention Type: DRUG; Name: omalizumab; Assigned to Arm(s): N/A
D: Arm Label: MEMP1972A 150 mg; Type: EXPERIMENTAL; Interventions: Drug: MEMP1972A | Arm Label: MEMP1972A 300 mg; Type: EXPERIMENTAL; Interventions: Drug: MEMP1972A | Arm Label: MEMP1972A 450 mg; Type: EXPERIMENTAL; Interventions: Drug: MEMP1972A | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: MEMP1972A; Assigned to Arm(s): MEMP1972A 300 mg | Intervention Type: DRUG; Name: MEMP1972A; Assigned to Arm(s): MEMP1972A 450 mg | Intervention Type: DRUG; Name: MEMP1972A; Assigned to Arm(s): MEMP1972A 150 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: RCT Evaluation of the Durham Connects Universal Newborn Nurse Home Visiting Program
Brief Summary: The aim of this randomized controlled trial (RCT) is to evaluate the impact and mechanisms of the Durham Connects (DC) brief universal nurse home-visiting program to prevent child maltreatment and improve child well-being. It is the first-ever RCT of a home-visiting program that is designed to prevent child maltreatment in an entire community population.

Evaluation of program impact will test three hypotheses: 1) Random assignment to the Durham Connects Program will be associated with lower rates of child maltreatment and emergency department maltreatment-related injuries, better pediatric care, better parental functioning, and better child well-being than assignment as control; 2) Intervention effect sizes will be larger for higher-risk groups; and 3) Community resource use and enhanced family functioning will mediate the positive impact of Durham Connects on outcomes.


Options:
A: Arm Label: Durham Connects Eligible Group; Type: EXPERIMENTAL; Interventions: Other: Durham Connects | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Durham Connects; Assigned to Arm(s): Durham Connects Eligible Group
B: Arm Label: Durham Connects Eligible; Type: EXPERIMENTAL; Interventions: Other: Durham Connects | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Durham Connects; Assigned to Arm(s): Durham Connects Eligible
C: Arm Label: mci guidance & peer social support; Type: EXPERIMENTAL; Interventions: Behavioral: mci guidance peer support | Arm Label: peer social support; Type: SHAM_COMPARATOR; Interventions: Behavioral: mci guidance peer support | Intervention Type: BEHAVIORAL; Name: mci guidance peer support; Assigned to Arm(s): mci guidance & peer social support, peer social support
D: Arm Label: Postpartum Visit 6 Weeks; Type: EXPERIMENTAL; Interventions: Behavioral: Postpartum Visit at 6 Weeks | Arm Label: Postpartum Visit 2 and 6 Weeks; Type: EXPERIMENTAL; Interventions: Behavioral: Postpartum Visit at 6 Weeks, Behavioral: Postpartum Visit at 2 Weeks | Intervention Type: BEHAVIORAL; Name: Postpartum Visit at 6 Weeks; Assigned to Arm(s): Postpartum Visit 2 and 6 Weeks, Postpartum Visit 6 Weeks | Intervention Type: BEHAVIORAL; Name: Postpartum Visit at 2 Weeks; Assigned to Arm(s): Postpartum Visit 2 and 6 Weeks

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase II Trial Comparing Capecitabine/CDDP(XP) and S-1/CDDP(SP) as the First-line Treatment for Advanced Gastric Cancer (XParTS II)
Brief Summary: The aim of this study is to elucidate the efficacy and safety of XP and SP for first-line treatment of Advanced Gastric Cancer.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Capecitabine, Drug: Oxaliplatin | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Oxaliplatin; Assigned to Arm(s): 1
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: TS-1 (S-1) | Arm Label: 2; Type: OTHER; Interventions: Procedure: Surgery | Intervention Type: DRUG; Name: TS-1 (S-1); Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Surgery; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: Irinotecan; Assigned to Arm(s): N/A
D: Arm Label: S-1,Cisplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: SP | Arm Label: Capecitabine, Cisplatin; Type: EXPERIMENTAL; Interventions: Drug: XP | Intervention Type: DRUG; Name: SP; Assigned to Arm(s): S-1,Cisplatin | Intervention Type: DRUG; Name: XP; Assigned to Arm(s): Capecitabine, Cisplatin

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Remote Ischemic Preconditioning in Patients Undergoing On-pump Coronary Artery Bypass Graft Surgery With Crystalloid Cardioplegic Arrest
Brief Summary: Remote ischemic preconditioning (RIPC) with transient upper limb ischemia/reperfusion reduces myocardial injury in patients undergoing on-pump coronary artery bypass (CABG) surgery with cross-clamp fibrillation or blood cardioplegia for myocardial protection. The present study assesses protection of heart, brain and kidney by RIPC under crystalloid cardioplegic arrest. The study also addresses safety and clinical outcome.


Options:
A: Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Control | Arm Label: Remote ischaemic conditioning; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Remote ischaemic preconditioning | Intervention Type: PROCEDURE; Name: Remote ischaemic preconditioning; Assigned to Arm(s): Remote ischaemic conditioning | Intervention Type: PROCEDURE; Name: Control; Assigned to Arm(s): Control
B: Arm Label: Group 1 Control (65 patients); Type: SHAM_COMPARATOR; Interventions: Drug: IV Normal saline | Arm Label: Group 2 (65 patients); Type: ACTIVE_COMPARATOR; Interventions: Other: Remote ischaemic preconditioning, Drug: IV Normal saline | Arm Label: Group 3 GTN (65 patients):; Type: EXPERIMENTAL; Interventions: Drug: IV Glyceryl trinitrate 2-5ml/h | Arm Label: • Group 4 RIPC+GTN (65 patients):; Type: EXPERIMENTAL; Interventions: Other: Remote ischaemic preconditioning, Drug: IV Glyceryl trinitrate 2-5ml/h | Intervention Type: OTHER; Name: Remote ischaemic preconditioning; Assigned to Arm(s): Group 2 (65 patients), • Group 4 RIPC+GTN (65 patients): | Intervention Type: DRUG; Name: IV Normal saline; Assigned to Arm(s): Group 1 Control (65 patients), Group 2 (65 patients) | Intervention Type: DRUG; Name: IV Glyceryl trinitrate 2-5ml/h; Assigned to Arm(s): Group 3 GTN (65 patients):, • Group 4 RIPC+GTN (65 patients):
C: Arm Label: RIPC; Type: ACTIVE_COMPARATOR; Interventions: Procedure: RIPC, Drug: isoflurane+sufentanil anesthesia | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Control, Drug: isoflurane+sufentanil anesthesia | Intervention Type: PROCEDURE; Name: RIPC; Assigned to Arm(s): RIPC | Intervention Type: PROCEDURE; Name: Control; Assigned to Arm(s): Control | Intervention Type: DRUG; Name: isoflurane+sufentanil anesthesia; Assigned to Arm(s): Control, RIPC
D: Intervention Type: PROCEDURE; Name: remote ischemic preconditioning; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Remote Ischemic Preconditioning in Patients Undergoing On-pump Coronary Artery Bypass Graft Surgery With Crystalloid Cardioplegic Arrest
Brief Summary: Remote ischemic preconditioning (RIPC) with transient upper limb ischemia/reperfusion reduces myocardial injury in patients undergoing on-pump coronary artery bypass (CABG) surgery with cross-clamp fibrillation or blood cardioplegia for myocardial protection. The present study assesses protection of heart, brain and kidney by RIPC under crystalloid cardioplegic arrest. The study also addresses safety and clinical outcome.


Options:
A: Intervention Type: PROCEDURE; Name: remote ischemic preconditioning; Assigned to Arm(s): N/A
B: Arm Label: Sevoflurane; Type: EXPERIMENTAL; Interventions: Procedure: Sevoflurane preconditioning | Arm Label: No Sevoflurane; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Sevoflurane preconditioning; Assigned to Arm(s): Sevoflurane
C: Arm Label: RIPC; Type: ACTIVE_COMPARATOR; Interventions: Procedure: RIPC, Drug: isoflurane+sufentanil anesthesia | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Control, Drug: isoflurane+sufentanil anesthesia | Intervention Type: PROCEDURE; Name: RIPC; Assigned to Arm(s): RIPC | Intervention Type: PROCEDURE; Name: Control; Assigned to Arm(s): Control | Intervention Type: DRUG; Name: isoflurane+sufentanil anesthesia; Assigned to Arm(s): Control, RIPC
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: remote ischemic postconditioning | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: remote ischemic postconditioning | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Procedure: remote ischemic postconditioning | Intervention Type: PROCEDURE; Name: remote ischemic postconditioning; Assigned to Arm(s): 1, 2, 3

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of NBP for Children of Divorce 15 Years Later
Brief Summary: The project is a 15-year follow-up of 240 young adults whose families participated in an experimental evaluation of the New Beginnings Program (NBP), a preventive intervention for divorced families. The NBP was provided in late childhood; the follow-up occurred in young adulthood. Families were randomly assigned to one of three conditions: mother program (MP), dual-component mother and child program (MPCP), or literature-control (LC) condition. Programs were designed to change several putative mediators of children's post-divorce mental health problems using empirically-supported change strategies. The investigators expected that the NBP would have either main or risk by program interactive effects on mental health and substance use problems and disorders, developmental tasks, parent-young adult relationships, physical health problems, and competencies, such that YAs who participated in NBP will have better functioning than YAs in the control condition. The investigators expected that the NBP will have either main or risk by program interactive effects on mothers' mental health; those in the NBP are expected to have fewer mental health problems than those in the control condition.


Options:
A: Arm Label: Mother Program; Type: EXPERIMENTAL; Interventions: Behavioral: New Beginnings Program | Arm Label: Mother Plus Child Program; Type: EXPERIMENTAL; Interventions: Behavioral: New Beginnings Program | Arm Label: Literature Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: New Beginnings Program; Assigned to Arm(s): Mother Plus Child Program, Mother Program
B: Arm Label: Örebro prevention program; Type: EXPERIMENTAL; Interventions: Behavioral: Örebro prevention program | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Business as usual | Intervention Type: BEHAVIORAL; Name: Örebro prevention program; Assigned to Arm(s): Örebro prevention program | Intervention Type: BEHAVIORAL; Name: Business as usual; Assigned to Arm(s): Control
C: Arm Label: Family Function Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Familias Unidas | Arm Label: Treatment as Usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Familias Unidas; Assigned to Arm(s): Family Function Intervention
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: brief intervention (cognitive-behavioral therapy) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: brief intervention (cognitive-behavioral therapy) | Intervention Type: BEHAVIORAL; Name: brief intervention (cognitive-behavioral therapy); Assigned to Arm(s): 1, 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of NBP for Children of Divorce 15 Years Later
Brief Summary: The project is a 15-year follow-up of 240 young adults whose families participated in an experimental evaluation of the New Beginnings Program (NBP), a preventive intervention for divorced families. The NBP was provided in late childhood; the follow-up occurred in young adulthood. Families were randomly assigned to one of three conditions: mother program (MP), dual-component mother and child program (MPCP), or literature-control (LC) condition. Programs were designed to change several putative mediators of children's post-divorce mental health problems using empirically-supported change strategies. The investigators expected that the NBP would have either main or risk by program interactive effects on mental health and substance use problems and disorders, developmental tasks, parent-young adult relationships, physical health problems, and competencies, such that YAs who participated in NBP will have better functioning than YAs in the control condition. The investigators expected that the NBP will have either main or risk by program interactive effects on mothers' mental health; those in the NBP are expected to have fewer mental health problems than those in the control condition.


Options:
A: Arm Label: Prevention programme; Type: EXPERIMENTAL; Interventions: Behavioral: Prevention programme | Arm Label: Control (treatment as usual); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Prevention programme; Assigned to Arm(s): Prevention programme
B: Arm Label: Mother Program; Type: EXPERIMENTAL; Interventions: Behavioral: New Beginnings Program | Arm Label: Mother Plus Child Program; Type: EXPERIMENTAL; Interventions: Behavioral: New Beginnings Program | Arm Label: Literature Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: New Beginnings Program; Assigned to Arm(s): Mother Plus Child Program, Mother Program
C: Arm Label: 1= Cognitive behavioral prevention of depression program; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive-behavioral prevention program | Arm Label: 2 = Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care | Intervention Type: BEHAVIORAL; Name: Cognitive-behavioral prevention program; Assigned to Arm(s): 1= Cognitive behavioral prevention of depression program | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): 2 = Usual care
D: Arm Label: Intrinsic Motivation; Type: EXPERIMENTAL; Interventions: Behavioral: MI + CATCH-IT Internet Site | Arm Label: Extrinsic Motivation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: BA (brief advice) + CATCH-IT Internet site | Intervention Type: BEHAVIORAL; Name: MI + CATCH-IT Internet Site; Assigned to Arm(s): Intrinsic Motivation | Intervention Type: BEHAVIORAL; Name: BA (brief advice) + CATCH-IT Internet site; Assigned to Arm(s): Extrinsic Motivation

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase II Study to Explore the Efficacy and Feasibility of Upfront Bi-monthly Rotations Between Everolimus and Pazopanib in Patients With Advanced or Metastatic Clear Cell Renal Cancer
Brief Summary: In this study will be examined whether alternating treatment between two classes of drugs (TKI's and m-TOR inhibitors) postpones or prevents drug resistance in patients with renal cancer.


Options:
A: Arm Label: Alternating regimen; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib, Drug: Everolimus | Arm Label: Sequential treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pazopanib, Drug: Everolimus | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Sequential treatment | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Sequential treatment | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Alternating regimen | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Alternating regimen | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Alternating regimen | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Alternating regimen
B: Arm Label: Pembrolizumab+Axitinib Combination Therapy; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab, Drug: Axitinib | Arm Label: Sunitinib Monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Intervention Type: BIOLOGICAL; Name: Pembrolizumab; Assigned to Arm(s): Pembrolizumab+Axitinib Combination Therapy | Intervention Type: DRUG; Name: Axitinib; Assigned to Arm(s): Pembrolizumab+Axitinib Combination Therapy | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib Monotherapy
C: Arm Label: Tivozanib hydrochloride; Type: EXPERIMENTAL; Interventions: Drug: Tivozanib hydrochloride | Arm Label: Sorafenib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sorafenib | Intervention Type: DRUG; Name: Tivozanib hydrochloride; Assigned to Arm(s): Tivozanib hydrochloride | Intervention Type: DRUG; Name: Sorafenib; Assigned to Arm(s): Sorafenib
D: Arm Label: Doublet; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Drug: Cabozantinib | Arm Label: Monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Arm Label: Triplet; Type: EXPERIMENTAL; Interventions: Biological: Ipilimumab | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Doublet | Intervention Type: DRUG; Name: Cabozantinib; Assigned to Arm(s): Doublet | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Monotherapy | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Triplet

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase II Study to Explore the Efficacy and Feasibility of Upfront Bi-monthly Rotations Between Everolimus and Pazopanib in Patients With Advanced or Metastatic Clear Cell Renal Cancer
Brief Summary: In this study will be examined whether alternating treatment between two classes of drugs (TKI's and m-TOR inhibitors) postpones or prevents drug resistance in patients with renal cancer.


Options:
A: Arm Label: A; Type: OTHER; Interventions: Drug: axitinib | Arm Label: B; Type: OTHER; Interventions: Drug: axitinib | Arm Label: C; Type: OTHER; Interventions: Drug: axitinib | Intervention Type: DRUG; Name: axitinib; Assigned to Arm(s): A | Intervention Type: DRUG; Name: axitinib; Assigned to Arm(s): B | Intervention Type: DRUG; Name: axitinib; Assigned to Arm(s): C
B: Arm Label: Alternating regimen; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib, Drug: Everolimus | Arm Label: Sequential treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pazopanib, Drug: Everolimus | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Sequential treatment | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Sequential treatment | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Alternating regimen | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Alternating regimen | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Alternating regimen | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Alternating regimen
C: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Cediranib Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Cediranib | Intervention Type: DRUG; Name: Cediranib; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Cediranib Placebo; Assigned to Arm(s): 1
D: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon-alfa | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: SU011248 | Intervention Type: DRUG; Name: Interferon-alfa; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: SU011248; Assigned to Arm(s): 1

Answer: B